about
S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utilityGenetic modifiers of non-alcoholic fatty liver disease progressionNon-alcoholic fatty liver disease: a practical approach to diagnosis and stagingNonalcoholic fatty liver disease: new treatmentsMutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibitionMutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in miceElafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue.Hypercoagulability in cirrhosis: causes and consequences.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis.Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis.Low Levels of 25-Hydroxy Vitamin D are Independently Associated with the Risk of Bacterial Infection in Cirrhotic Patients.Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver diseaseCellular senescence drives age-dependent hepatic steatosis.MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum.TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease is associated with higher levels of objectively measured sedentary behaviour and lower levels of physical activity than matched healthy controls.Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosisRepublished: Non-alcoholic fatty liver disease: a practical approach to treatment.Differential DNA methylation of genes involved in fibrosis progression in non-alcoholic fatty liver disease and alcoholic liver disease.Plasma DNA methylation: a potential biomarker for stratification of liver fibrosis in non-alcoholic fatty liver disease.Multigenerational epigenetic adaptation of the hepatic wound-healing responseMouse models in non-alcoholic fatty liver disease and steatohepatitis research.Genetic predisposition in NAFLD and NASH: impact on severity of liver disease and response to treatment.Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial.Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans.The genetics of NAFLD.Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification.The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.Piloting a multidisciplinary clinic for the management of non-alcoholic fatty liver disease: initial 5-year experience.An overview of the genetics, mechanisms and management of NAFLD and ALD.Genetics of Alcoholic Liver Disease.Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease.Effects of Exercise on Liver Fat and Metabolism in Alcohol Drinkers.Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.Rifaximin in non-alcoholic steatohepatitis: An open-label pilot study.Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.Parenchymal extinction: coagulation and hepatic fibrogenesis.
P50
Q26829356-77D25DB8-1E12-4051-B555-472A15709030Q26997101-1D6954E9-332E-4B46-A89D-665047172830Q27006131-82D34D3C-162B-44BC-952C-012AC1EA9738Q27021161-BCC901BC-8628-4B09-BE3E-C9A79D70525CQ28302883-B42A82B8-9616-409B-83E9-E2E008AF9609Q28534250-4A3E8680-F320-406E-983C-A224CF61DDEBQ30277347-0EFAA235-B5B8-45D6-B0F1-ACE8DD198238Q33359272-9AAFE980-0682-48F0-9B80-079EEA06070EQ33396091-879D502B-2EAA-4B77-A8AA-69872272864CQ33574413-3ED6BC9E-9D5F-42BB-80A3-61FC44B214ACQ33574413-A732C32E-1636-4273-8783-655FD723BA22Q33639969-62C6A8A4-D908-462F-A4B5-0908078872CCQ33701184-B12244DC-A25F-45D7-A5D6-1EA06552B04CQ33728918-AA69E787-D0F6-4345-8CCF-70FA15765065Q33810220-66F78308-D7F2-4C53-B2A6-BF62B8BF675FQ33866766-2673DD4D-9315-4C7E-B196-C48863BEC524Q34518314-436A944C-3537-49E3-B728-43C58B1B9915Q34785862-0CF46F7F-8297-4B40-B8E9-A6D38945EEC4Q34819180-18D31472-6E51-4F77-B5E2-0FDD2654CDE7Q35056710-D9F2A308-B9D3-41AE-9043-891ABB687846Q35135556-9EB53DA8-1FAC-4A9D-BBA7-EF11485049E7Q35337252-8018E053-48E8-4B89-AB59-A68C14F4A0EEQ35965687-AEE51472-AF24-4750-8F14-36C390E6A46FQ36374096-8F418809-6E3D-4F33-A37C-DC568ACFE95BQ36377266-75312814-A3FF-4587-9495-9C47F1B4CA09Q37362755-6F596FF9-BB5E-465A-AEF4-37BDD1003477Q37420413-FC466B5F-C210-4427-86F3-11B6B062E09DQ37541501-45A53BA8-D93B-42C2-8230-44101EBCEC89Q37643487-4414ACD4-EF5A-4D7B-87B9-E1C4010A171BQ38141714-29712C5C-6C51-41F6-A62B-17320EF26235Q38204970-3A4EB28E-F72D-41F9-B601-0ACB2EA92C9CQ38588336-09A722D2-7473-4D30-A6BD-8186413713BBQ38609085-E4474242-B89A-422A-9274-9564D503C880Q38658494-E95BAD4E-D7F5-43C7-B71B-9063D3FB6057Q38671642-04CA5B6C-265C-4C12-87FB-A59014DABE6FQ38731798-6C420FF6-572D-4863-A876-8E71361E6451Q38787752-522E2E3F-CAEB-40DE-A8D1-F2D89BC86514Q38802973-0D26387D-4E52-40A9-AFAE-56162F031E2CQ38829371-ADD08636-C273-40E7-ABEE-30E968172499Q38897034-5E01DE92-3087-43BC-808F-5D7E23BC7B2B
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Quentin M Anstee
@ast
Quentin M Anstee
@en
Quentin M Anstee
@es
Quentin M Anstee
@nl
Quentin M Anstee
@sl
type
label
Quentin M Anstee
@ast
Quentin M Anstee
@en
Quentin M Anstee
@es
Quentin M Anstee
@nl
Quentin M Anstee
@sl
altLabel
Quentin M. Anstee
@en
prefLabel
Quentin M Anstee
@ast
Quentin M Anstee
@en
Quentin M Anstee
@es
Quentin M Anstee
@nl
Quentin M Anstee
@sl
P1053
L-2981-2013
P106
P1153
12781808200
P21
P31
P3829
P496
0000-0002-9518-0088